Elan Pharma International Limited

Fournier Laboratories Ireland Limited

Alkermes Pharma Ireland Limited

Rhodes Pharmaceuticals L.p.

Flak Pharma International, Ltd.

Rajeev A Jain

Stephen B Ruddy

Rakesh A Patel

Niels Peter Ryde

Tuula Ryde

Evan E Gustow

Michael John Wilkins

Eugene Rex Cooper

Maurice Joseph Anthony Clancy

John A Bullock

Janet Elizabeth Codd

John R Chippari

John L Schaefer

Joost Strasters

Jon Swanson

H William Bosch

Gary G Liversidge

John G Devane

Robert Hontz

Kenneth Iain Cumming

Kevin D Ostrander

Douglas C Hovey

Laura Kline

Sibao Chen

Gerard P Frunzi

Linden Wei

Greta G Cary

Elaine Merisko-Liversidge

Kenneth Ian Cumming

Disclosed herein are pharmaceutical compositions having a mixture of at least one active agent and an ion exchange resin, such that the composition releases about 75% or more of the at least one active agent within about 1 hour as measured by in-vitro dissolution in a USP Apparatus 2 (paddle) at about 50 rpm in about 900 ml 0.1N HCl at about 37&#xb0; C. and related methods. Also disclosed herein are pharmaceutical compositions having a mixture of a drug susceptible to abuse, a non-opioid analgesic and an ion exchange resin, the composition further including at least one gelling agent and related methods.

Pharmaceutical resinate compositions and methods of making and using thereof

Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.

In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions

Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the agent following administration. The novel compositions release the agent following administration for a time period ranging from about 2 to about 24 hours or longer.

Controlled-release nanoparticulate compositions

The present invention is directed to nanoparticulate compositions comprising glipizide. The glipizide particles of the composition preferably have an effective average particle size of less than about 2 microns.

Glipizide compositions

Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors

The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm.

Nanoparticulate fibrate formulations

Methods of treatment using nanoparticulate fenofibrate compositions

[object Object]

Disclosed is a rapidly disintegrating solid oral dosage form of a poorly soluble active ingredient and at least one pharmaceutically acceptable water-soluble or water-dispersible excipient, wherein the poorly soluble active ingredient particles have an average diameter, prior to inclusion in the dosage form, of less than about 2000 nm. The dosage form of the invention has the advantage of combining rapid presentation and rapid dissolution of the active ingredient in the oral cavity.

Rapidly disintegrating solid oral dosage form

Described are solid dose nanoparticulate naproxen formulations having high rates of dissolution. The solid dose nanoparticulate naproxen formulations can comprise an alkali compound, which functions to increase the dissolution rate of the naproxen following administration. Alternatively, the solid dose nanoparticulate naproxen formulation can comprise an alkali compound and an acidic compound, which can react together to form carbon dioxide. The formed carbon dioxide can also aid in increasing the dissolution rate of the naproxen following administration. Also described are solid dose nanoparticulate naproxen formulations having a decreased concentration of a binder/disintegrant agent. Such compositions also provide an increased rate of dissolution of naproxen following administration.

Solid dose form of nanoparticulate naproxen

Growing community of inventors

Framingham, MA, United States of America

Rajeev A Jain